Search

Your search keyword '"Ciaccio, Antonio"' showing total 123 results

Search Constraints

Start Over You searched for: Author "Ciaccio, Antonio" Remove constraint Author: "Ciaccio, Antonio"
123 results on '"Ciaccio, Antonio"'

Search Results

4. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

5. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

6. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

8. Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project

10. Predicting de‐novoportal vein thrombosis after HCV eradication: A long‐term competing risk analysis in the ongoing PITER cohort

11. Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR plus ), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients : a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project

14. Liver toxicity associated to novel cyclin-dependent kinase inhibitor ribociclib in a cohort of advanced breast cancer patients

15. Corrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581]

16. Clinical treatment of cholangiocarcinoma: an updated comprehensive review

18. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581]

19. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

20. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

21. Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach

23. Health related quality of life in chronic liver diseases

24. Comparison of three therapeutic regimens for genotype‐3 hepatitis C virus infection in a large real‐life multicentre cohort

25. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

26. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

28. Drug Prescription and Delirium in Older Inpatients: Results From the Nationwide Multicenter Italian Delirium Day 2015-2016

29. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581]

30. Clinical outcome indicators in chronic hepatitis B and C: A primer for value‐based medicine in hepatology

32. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era

33. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

34. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis

35. Clinical outcome indicators in chronic hepatitis B and C: A primer for value‐based medicine in hepatology.

36. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?

37. Impact of multidisciplinary team approach to liver tumors: 5-Years experience

38. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis

39. Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study

40. Cost-effectiveness of Sofosbuvir plus Ledipasvir Antiviral Treatment for Elderly Patients with Chronic Hepatitis C Genotype 1

41. Management of Chronic hepatitis C (CHC) Genotype 1 treatment-naive patients in an era of rising opportunities and costs - A cost-effectiveness analysis of treatment options

43. The impact of liver disease on the health-related quality of life

44. Trattamento con Sofosbuvir e Ribavirina nei pazienti hcv-positivi listati per il trapianto di fegato: un analisi di costo-efficacia

45. Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study)

46. Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study

47. Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study)

48. A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators

49. Sofosbuvir and ribavirinin in HCV-infected patients listed for liver transplantation: A cost-effectiveness analysis

50. Generation and Performance of Outcome Indicators in Liver Disease: The Value Based Medicine in Hepatology Study (VBMH)

Catalog

Books, media, physical & digital resources